Will Boston Scientific's New Boss Be Allowed To Be Boss?
Will Boston Scientific's new CEO, Jim Tobin, be able to get Chairman Peter Nicholas to leave him alone and let him run the company? He's had this trouble before at Baxter and Biogen.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.